Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT04107675 is registered in ClinicalTrials.gov with Zambon SpA as lead sponsor.

NCT NCT04107675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04107675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Zambon SpA
Phase
Phase 2
Overall status
Terminated
Start date
February 11, 2020
Completion date
December 15, 2022
Enrollment
6 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiolitis obliterans syndrome (bos), gvhd, chronic, stem cell transplant complications